Comparative Pharmacology
Head-to-head clinical analysis: BUSULFAN versus THIOTEPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUSULFAN versus THIOTEPA.
BUSULFAN vs THIOTEPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Busulfan is a bifunctional alkylating agent that crosslinks DNA, primarily at guanine N7 positions, leading to DNA strand breaks and inhibition of DNA replication and transcription. It is cell cycle phase-nonspecific.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
1-4 mg/day orally for remission induction in CML; 0.8-1 mg/kg every 6 hours orally for 4 days as part of myeloablative conditioning with cyclophosphamide.
0.3-0.4 mg/kg intravenously every 1-4 weeks; or 0.5-1 mg/kg intravenously every 2-4 weeks (commonly 60 mg/m² IV every 1-4 weeks).
None Documented
None Documented
Terminal elimination half-life is 2.5 to 4 hours (mean ~2.6 hours) after oral administration; prolonged to 3-5 hours with high-dose regimens. Half-life may increase with hepatic impairment.
Clinical Note
moderateBusulfan + Digoxin
"Busulfan may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateThiotepa + Digoxin
"Thiotepa may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateBusulfan + Digitoxin
"Busulfan may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateThiotepa + Digitoxin
"Thiotepa may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life is approximately 1.5-4.5 hours. Clinically, due to rapid clearance, dosing intervals are typically every 1-4 weeks.
Renal (10-50% unchanged), hepatic metabolism (primarily via glutathione S-transferases) with metabolites excreted in bile and urine. Fecal excretion minimal (<5%).
Primarily renal; 60-70% excreted unchanged in urine within 24-72 hours. Minor biliary/fecal elimination accounts for <10%.
Category C
Category D/X
Alkylating Agent
Alkylating Agent